Cadrenal Therapeutics (CVKD) Competitors $10.33 -0.09 (-0.86%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$10.35 +0.02 (+0.19%) As of 08/1/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CVKD vs. BYSI, PLRX, ELUT, ORMP, QNCX, WHWK, CABA, MIST, EPIX, and JMACShould you be buying Cadrenal Therapeutics stock or one of its competitors? The main competitors of Cadrenal Therapeutics include BeyondSpring (BYSI), Pliant Therapeutics (PLRX), Elutia (ELUT), Oramed Pharmaceuticals (ORMP), Quince Therapeutics (QNCX), Whitehawk Therapeutics (WHWK), Cabaletta Bio (CABA), Milestone Pharmaceuticals (MIST), ESSA Pharma (EPIX), and Maxpro Capital Acquisition (JMAC). These companies are all part of the "pharmaceutical products" industry. Cadrenal Therapeutics vs. Its Competitors BeyondSpring Pliant Therapeutics Elutia Oramed Pharmaceuticals Quince Therapeutics Whitehawk Therapeutics Cabaletta Bio Milestone Pharmaceuticals ESSA Pharma Maxpro Capital Acquisition Cadrenal Therapeutics (NASDAQ:CVKD) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations. Which has higher earnings & valuation, CVKD or BYSI? Cadrenal Therapeutics has higher earnings, but lower revenue than BeyondSpring. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCadrenal TherapeuticsN/AN/A-$10.65M-$9.26-1.12BeyondSpring$1.75M47.69-$11.12MN/AN/A Does the media refer more to CVKD or BYSI? In the previous week, Cadrenal Therapeutics' average media sentiment score of 0.00 equaled BeyondSpring'saverage media sentiment score. Company Overall Sentiment Cadrenal Therapeutics Neutral BeyondSpring Neutral Is CVKD or BYSI more profitable? BeyondSpring's return on equity of 0.00% beat Cadrenal Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cadrenal TherapeuticsN/A -244.94% -181.94% BeyondSpring N/A N/A N/A Do institutionals and insiders believe in CVKD or BYSI? 7.9% of Cadrenal Therapeutics shares are owned by institutional investors. Comparatively, 40.3% of BeyondSpring shares are owned by institutional investors. 48.6% of Cadrenal Therapeutics shares are owned by company insiders. Comparatively, 29.3% of BeyondSpring shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more volatility & risk, CVKD or BYSI? Cadrenal Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. Comparatively, BeyondSpring has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500. Do analysts prefer CVKD or BYSI? Cadrenal Therapeutics presently has a consensus target price of $32.00, indicating a potential upside of 209.78%. Given Cadrenal Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Cadrenal Therapeutics is more favorable than BeyondSpring.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cadrenal Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00BeyondSpring 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryCadrenal Therapeutics beats BeyondSpring on 6 of the 10 factors compared between the two stocks. Get Cadrenal Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CVKD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CVKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVKD vs. The Competition Export to ExcelMetricCadrenal TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.49M$3.00B$5.48B$9.51BDividend YieldN/A2.43%4.73%4.08%P/E Ratio-1.1217.6228.6723.80Price / SalesN/A179.18373.9066.65Price / CashN/A41.9535.4557.96Price / Book2.488.508.275.55Net Income-$10.65M-$55.06M$3.24B$259.03M7 Day Performance-10.10%-3.98%-3.69%-4.59%1 Month Performance-16.96%9.59%4.33%4.46%1 Year PerformanceN/A6.72%25.95%18.03% Cadrenal Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVKDCadrenal Therapeutics2.1558 of 5 stars$10.33-0.9%$32.00+209.8%N/A$20.49MN/A-1.124Upcoming EarningsGap DownBYSIBeyondSpringN/A$1.88-13.8%N/A+6.7%$87.89M$1.75M0.0080PLRXPliant Therapeutics3.6375 of 5 stars$1.45+1.4%$13.31+818.1%-89.0%$87.78M$1.58M-0.4090Upcoming EarningsELUTElutia3.4514 of 5 stars$2.13+0.5%$8.00+275.6%-40.4%$86.96M$23.71M-1.10180News CoverageUpcoming EarningsGap DownORMPOramed Pharmaceuticals0.7783 of 5 stars$2.12flatN/A-10.5%$86.59M$1.34M-4.8210News CoverageAnalyst RevisionQNCXQuince Therapeutics2.2757 of 5 stars$1.90+0.5%$8.00+321.1%+125.9%$85.94MN/A-1.3760Short Interest ↑WHWKWhitehawk TherapeuticsN/A$1.85+2.8%N/AN/A$84.80M$25.98M11.5640CABACabaletta Bio1.7951 of 5 stars$1.64-1.8%$14.43+779.8%-79.1%$84.74MN/A-0.6550Upcoming EarningsMISTMilestone Pharmaceuticals1.6437 of 5 stars$1.49-5.7%$7.00+369.8%+2.9%$84.47M$1M-1.9130Upcoming EarningsShort Interest ↑EPIXESSA Pharma1.1674 of 5 stars$1.87-0.5%$2.00+7.0%-63.4%$83.45MN/A-2.9750News CoverageUpcoming EarningsJMACMaxpro Capital AcquisitionN/A$6.21-3.7%N/A+2,963.2%$83.39MN/A0.002,021News CoverageGap Up Related Companies and Tools Related Companies BYSI Competitors PLRX Competitors ELUT Competitors ORMP Competitors QNCX Competitors WHWK Competitors CABA Competitors MIST Competitors EPIX Competitors JMAC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CVKD) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cadrenal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cadrenal Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CVKD Stock Alerts